With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...

GLP-1 drugs like Ozempic, Mounjaro, Zepbound, originally for adults, are now prescribed for adolescents with obesity, showing ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

A NEW potential side effect of ‘Ozempic-style’ fat jabs has been discovered, putting experts on edge. The injections have ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.